StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
ALKSAlkermes plc.
stockpulse.co.kr
Nasdaq
$43.63▲ 0.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $7.27BShares out 1.700M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

25
  • 10.9After-hours26.10.10 07:18
    4Ownership#●●●

    Alkermes plc.

    Insider Joshua Reed of Alkermes plc. reported a change in beneficial ownership of securities effective October 8, 2026. This filing serves as a Form 4 statement regarding executive equity transactions.…more

    $43.63+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.9After-hours26.10.10 07:16
    4Ownership

    Alkermes plc.

    Anne Whitaker, an executive at Alkermes plc., reported a change in beneficial ownership of securities on October 7, 2026. This filing is a standard Form 4 report disclosing insider equity transactions.…more

    $43.63+0.05%vs prev close
    View filingShare
  • 10.2After-hours26.10.03 07:22
    4Ownership

    Alkermes plc.

    Alkermes plc. insider David Joseph Gaffin filed a Form 4 statement on October 2, 2026, regarding changes in his beneficial ownership of securities. This filing serves as an official record of the insider's stock transaction activity.…more

    $43.63+0.05%vs prev close
    View filingShare

24 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.13Pre-market26.10.13 20:05
    #●●●#●●●

    Alkermes to Present Sleep Medicine Research at ESRS 2026

    Alkermes plans to share clinical data for its narcolepsy and idiopathic hypersomnia treatments at the upcoming ESRS Congress. The presentations will highlight key phase study results and long-term safety data for its sleep medicine portfolio.…more

    $43.63+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.21Regular26.09.22 02:13

    ●●●●●●●● ●●●●● ●●●●●●

    Alkermes announced positive topline results from a Phase 1 study of its ADHD drug candidate, ALKS 7290, showing symptom reduction and a favorable safety profile. While the company has moved to Phase 2 trials, the drug remains in early-stage development.…more

    $43.63+0.05%vs prev close
    ShareBenzinga
  • 9.21Pre-market26.09.21 20:06

    ●●●●●●●● ●●●●● ●●●●●●

    Alkermes announced positive topline results from a phase 1 study of its ADHD candidate, ALKS 7290, demonstrating clinical improvements and good tolerability. These findings support the dosing strategy for the company's ongoing phase 2 clinical trial.…more

    $43.63+0.05%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →